Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation

Myelodysplastic syndromes (MDS) are a diverse group of clonal myeloid disorders characterized by ineffective hematopoiesis, cytopenias, and a tendency towards transformation to acute myeloid leukemia (AML) [1]. Based on the International Prognostic Scoring System (IPSS), patients with MDS are prognostically stratified into either lower-risk (low and intermediate-1) or higher-risk (intermediate-2 and high) disease [2]. By the revised IPSS, lower-risk includes very low, low, and a fraction of intermediate-risk patients [3,4].

Source: Leukemia Research - September 14, 2018 Category: Hematology Authors: Yasmin Abaza, Juliana E. Hidalgo-Lopez, Srdan Verstovsek, Elias Jabbour, Farhad Ravandi, Gautam Borthakur, Zeev Estrov, Yesid Alvarado, Jan Burger, Heather Schneider, Kelly A. Soltysiak, Yue Wei, Hagop M. Kantarjian, Carlos E. Bueso-Ramos, Guillermo Garci Tags: Research paper Source Type: research